Emerging Research Grants (ERG) Applications Are Open

By Christopher Geissler, Ph.D.

ERG_logo-new.png

Applications for the 2021-2022 Emerging Research Grants (ERG) cycle opened yesterday, Monday, November 2.

Through the Emerging Research Grants (ERG) program, Hearing Health Foundation (HHF) provides seed money to researchers working across the entire spectrum of hearing research and balance research, including many underfunded areas of otology. The ERG program has since 1958 played a foundational role in the careers of many academic researchers and clinicians in otolaryngology and related hearing and balance fields. As the program’s remit is so broad, HHF solicits applications for ERG awards under a number of opportunity types, including:

Please see the below key details about the program.

APPLICATIONS OPEN

November 2, 2020

APPLICATION DEADLINE

February 26, 2021

FUNDING

Up to $50,000 per year for each project for an initial period of one year, renewable for one additional year.

PROGRAM DATE

October 1, 2021 – September 30, 2022

FUNDING DECISION NOTIFICATION

First week of August 2021

GRANT PAYMENT SCHEDULE

October and April 

Within the scientific community, the ERG program is known as a competitive process that awards grants to only the most promising investigators. Recipients are exceptionally well-positioned to win funding from the National Institutes of Health (NIH), leading to dramatic innovations in the field. In fact, ERG alumni have gone on to be awarded an average of $91 for every dollar of their ERG grant.

While early career researchers are especially encouraged to apply, ERG awards are open to both early career researchers and senior investigators.

Christopher Geissler, Ph.D., is HHF’s Director of Program and Research Support. To remain up-to-date on ERG funding opportunities, including notifications about the upcoming grant cycle, subscribe at hhf.org/grants. To learn more about ERG, including past grant recipients and their projects, see hhf.org/erg.

Print Friendly and PDF

BLOG ARCHIVE